All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Atrasentan Hydrochloride
Therapeutic Area: Nephrology Product Name: ABT-627
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Aduro Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger October 05, 2020
Details:
Chinook will focus on advancing its product candidates for kidney disease, including, Planned Phase 3 and Phase 2 trials of atrasentan, going Phase 1b and future clinical trials of BION-1301, planned Phase 1 trial of CHK-336 and additional R&D programs related to CKD.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Atrasentan Hydrochloride
Therapeutic Area: Nephrology Product Name: ABT-627
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: EcoR1 Capital
Deal Size: $106.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 18, 2020
Details:
Net proceeds will support company's planned phase 2 and phase 3 trials of atrasentan, an investigational selective endothelin receptor antagonist, in development for the treatment of IgA nephropathy and other primary glomerular diseases including other clinical activities.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Voclosporin
Therapeutic Area: Nephrology Product Name: ISA247
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 27, 2020
Details:
The Company intends to use the net proceeds of the Offering for pre-commercialization and launch activities, research and development, as well as working capital and general corporate purposes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Voclosporin
Therapeutic Area: Nephrology Product Name: ISA247
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2020
Details:
The FDA grants priority review designation to the evaluation of drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment for serious conditions.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Voclosporin
Therapeutic Area: Nephrology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2020
Details:
The data showed that pre-specified confirmed estimated glomerular filtration rate (eGFR) decreases of over 30% were similar in both AURORA trial patient groups, with 10.1% reported in the voclosporin group and 10.2% in the control arm.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Voclosporin
Therapeutic Area: Nephrology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2020
Details:
The presented data demonstrated clinically meaningful benefits of voclosporin for trial participants across ethnicities and self-reported race.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Atrasentan Hydrochloride
Therapeutic Area: Nephrology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Aduro Biotech
Deal Size: $225.0 million Upfront Cash: $200.0 million
Deal Type: Merger June 02, 2020
Details:
Combined company will operate as chinook therapeutics and advance pipeline of clinical-stage programs in kidney diseases, led by Atrasentan and Bion-1301 in IGA nephropathy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Voclosporin,Mycophenolic Acid,Corticosteroids
Therapeutic Area: Nephrology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2020
Details:
Clinical data from its AURORA Phase 3 trial will be highlighted in a late-breaking oral presentation during the National Kidney Foundation 2020 Spring Clinical Meetings.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Voclosporin
Therapeutic Area: Nephrology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2020
Details:
The rolling NDA allows completed portions of an NDA to be submitted and reviewed by the Agency on an ongoing basis.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
